FCGR3A and brain cancer: The V158F polymorphism of FcγRIIIA, which is associated with higher therapeutic response to RTX (31–33) or to the anti-ErB-2 mAb trastuzumab (TTZ) used in brain cancer (34), has also been related to interindividual variations in FcγRIIIA expression (35, 36), although this is not confirmed (9, 37).